Business
Kalaris Announces Closing of Merger with AlloVir
Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina Currently enrolling nAMD patients in a Phase 1 trial, with initial data from Part 1 of the trial expected in the second half of 2025 Post-transaction cash of approximately $100 million expected to fund operations into the fourth quarter of 2026 Shares expected to trade on Nasdaq
About this update from Kalaris Therapeutics, Inc.
[{"type":"image","alt":"Kalaris Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Kalaris Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":140,"height":40,"url":"https://media.zenfs.com/en/globenewswire.com/fdbb7c94867cf52e75aaccd6c74b0d21"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/omsWelxSjfpb3wGCdv4fDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/fdbb7c94867cf52e75aaccd6c74b0d21","width":140,"height":40}},"lazy":false},{"type":"text","content":"Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina","length":219,"tagName":"p"},{"type":"text","content":"Currently enrolling nAMD patients in a Phase 1 trial, with initial data from Part 1 of the trial expected in the second half of 2025","length":132,"tagName":"p"},{"type":"text","content":"Post-transaction cash of approximately $100 million expected to fund operations into the fourth quarter of 2026","length":112,"tagName":"p"},{"type":"text","content":"Shares expected to trade on Nasdaq under “KLRS”, effective March 19, 2025","length":73,"tagName":"p"},{"type":"text","content":"PALO ALTO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS)(“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent diseases of the retina, today announced the completion of its previously announced merger with AlloVir, Inc. (“AlloVir”). The combined company will operate under the name Kalaris Therapeutics, Inc. and its shares are expected to begin trading on The Nasdaq Global Market on March 19, 2025 under the ticker symbol “KLRS.”","length":550,"tagName":"p"},{"type":"text","content":"Kalaris is currently developing TH103, a novel, differentiated anti-vascular endothelial growth factor (“VEGF”) agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina. TH103 was specifically engineered to address the limitations of current neovascular Age-related Macular Degeneration (“nAMD”) therapies and has demonstrated both potent anti-VEGF activity and sustained ocu...